Industry Vertical | Planned
AI Strategy for Pharma & Biotech
Help pharma mid-market companies move from AI pilots to scaled deployment—accounting for GxP validation and compliance costs.
The Challenge
Traditional pharma companies lag AI-native firms by 5x in adoption. 80% of AI projects remain stuck in pilot stage, and ROI calculations ignore validation, pharmacovigilance, and change control costs.
5x
Adoption Lag vs AI-Native
80%
Stuck in Pilot Stage
€16.5B
Global Pharma AI by 2034
Planned Capabilities
- 1Pharma-specific AI use case library (R&D, clinical trials, manufacturing, quality)
- 2GxP compliance mapping for AI validation requirements
- 3Pilot-to-production pathway framework
- 4TCO reality check including hidden validation costs
Be first to access AI Readi Pharma
Be among the first to access AI Readi Pharma when it launches.